CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1100682 · Fiscal year ends 12/27
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.2%
TTM net income YoY148.8%
TTM EPS YoY160.5%
Revenue 3-yr CAGR-1.9%
Net income 3-yr CAGR-56.1%
Margins
Gross margin—
Operating margin4.0%
Net margin1.0%
FCF margin10.0%
EBITDA margin11.2%
Returns
ROE1.2%
ROA0.5%
ROIC (approx.)2.3%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets56.0%
Debt / equity0.76x
Current ratio1.41x
Interest coverage1.45x
Cash quality & payout
Operating cash flow / net income15.49x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-26 | 2026Q22026-06-27 | 2026Q12026-03-28 | 2025Q4*2025-12-27 | 2025Q32025-09-27 | 2025Q22025-06-28 | 2025Q12025-03-29 | 2024Q4*2024-12-28 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $982.73M | $1.00B | $995.83M | $994.23M | $1.00B | $1.03B | $984.17M | $1.00B |
| SG&A expense | $140.59M | $228.90M | $159.42M | $196.14M | $177.59M | $191.55M | $177.80M | $195.71M |
| Operating income | $202.64M | $119.89M | $119.90M | -$283.44M | $133.80M | $100.13M | $74.67M | -$167.69M |
| Interest expense | $28.52M | $30.34M | $26.74M | $23.77M | $25.40M | $29.97M | $27.88M | $28.23M |
| Income tax | -$163.79M | $53.93M | -$15.14M | -$17.81M | $31.64M | $18.73M | $10.10M | -$3.04M |
| Net income | $333.07M | -$1.48M | -$14.84M | -$276.56M | $54.42M | $52.33M | $25.47M | -$214.50M |
| EBITDA | $274.90M | $187.18M | $187.05M | -$205.16M | $218.96M | $219.64M | $195.03M | -$65.58M |
| EPS (basic) | 6.97 | -0.03 | -0.30 | — | 1.11 | 1.06 | 0.50 | — |
| EPS (diluted) | 6.86 | -0.03 | -0.30 | — | 1.10 | 1.06 | 0.50 | — |
| Weighted avg. shares (diluted) | 48.58M | 48.02M | 48.95M | — | 49.43M | 49.32M | 50.85M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $200.38M | $192.03M | $191.83M | $213.77M | $207.10M | $182.82M | $229.36M | $205.57M |
| Receivables | $735.30M | $711.75M | $700.25M | $708.86M | $734.48M | $767.57M | $756.63M | $720.91M |
| Inventory | $319.64M | $346.26M | $359.72M | $299.10M | $302.55M | $279.55M | $290.16M | $278.54M |
| Current assets | $1.54B | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B |
| PP&E, net | $1.50B | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B |
| Goodwill | $3.08B | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B |
| Intangibles | $238.66M | $253.17M | $248.99M | $340.00M | $571.09M | $602.45M | $655.71M | $723.40M |
| Total assets | $7.45B | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B |
| Current liabilities | $1.09B | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994.10M |
| Short-term debt | $2.10M | $5.46M | $6.70M | $166,000 | $54,000 | $98,000 | $121,000 | $155,000 |
| Long-term debt | $2.44B | $2.62B | $2.66B | $2.14B | $2.19B | $2.33B | $2.51B | $2.24B |
| Total debt | $2.45B | $2.63B | $2.67B | $2.14B | $2.19B | $2.33B | $2.51B | $2.24B |
| Total liabilities | $4.18B | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B |
| Shareholders' equity | $3.23B | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B |
| Net debt | $2.25B | $2.43B | $2.48B | $1.92B | $1.98B | $2.15B | $2.28B | $2.03B |
| Shares outstanding | 47.88M | 47.73M | 48.17M | 49.22M | 49.22M | 49.21M | 49.12M | 51.14M |
| Cash flow statement | ||||||||
| Operating cash flow | $254.09M | $179.72M | $41.08M | $147.52M | $213.83M | $204.60M | $171.70M | $159.36M |
| Capital expenditure | $46.81M | $31.11M | $55.91M | $88.95M | $35.58M | $35.30M | $59.32M | $75.62M |
| Free cash flow | $207.28M | $148.62M | -$14.83M | $58.57M | $178.25M | $169.31M | $112.37M | $83.75M |
| Investing cash flow | $10.23M | $28.10M | -$407.85M | -$92.81M | -$33.70M | -$37.34M | -$45.48M | -$76.10M |
| Financing cash flow | -$254.15M | -$164.66M | $347.72M | -$51.86M | -$152.62M | -$226.92M | -$105.33M | -$75.88M |
| Depreciation & amortization | $72.26M | $67.29M | $67.15M | $78.28M | $85.16M | $119.51M | $120.36M | $102.10M |
| Stock-based compensation | $20.77M | $19.78M | $22.38M | $17.63M | $23.27M | $17.05M | $13.13M | $17.23M |
| Share buybacks | $224,000 | $115.60M | $208.28M | $96,000 | $93,000 | $7.35M | $353.13M | $124,000 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.